See more : Fulton Financial Corporation (FULTP) Income Statement Analysis – Financial Results
Complete financial analysis of Moderna, Inc. (0QF.F) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Moderna, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- INNOX Advanced Materials Co.,Ltd. (272290.KQ) Income Statement Analysis – Financial Results
- Nantong Haixing Electronics Co., Ltd. (603115.SS) Income Statement Analysis – Financial Results
- Baker Hughes Company (0RR8.L) Income Statement Analysis – Financial Results
- GeneOne Life Science, Inc. (011000.KS) Income Statement Analysis – Financial Results
- Banco Comercial Português, S.A. (BCP.LS) Income Statement Analysis – Financial Results
Moderna, Inc. (0QF.F)
About Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.75B | 19.26B | 17.74B | 274.49M | 48.04M | 122.51M | 176.97M | 101.54M |
| Cost of Revenue | 4.69B | 5.42B | 2.62B | 7.93M | 0.00 | -12.56M | 0.00 | 0.00 |
| Gross Profit | 2.06B | 13.85B | 15.12B | 266.56M | 48.04M | 135.07M | 176.97M | 101.54M |
| Gross Profit Ratio | 30.52% | 71.88% | 85.24% | 97.11% | 100.00% | 110.25% | 100.00% | 100.00% |
| Research & Development | 4.85B | 3.30B | 1.99B | 1.37B | 496.31M | 454.08M | 410.46M | 274.72M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 109.62M | 94.25M | 64.72M | 57.45M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.55B | 1.13B | 567.00M | 188.27M | 109.62M | 94.25M | 64.72M | 57.45M |
| Other Expenses | -94.00M | -45.00M | -735.00M | -528.91M | -12.17M | 1.84M | -1.88M | -2.71M |
| Operating Expenses | 6.30B | 4.43B | 1.82B | 1.03B | 593.76M | 535.78M | 446.33M | 325.31M |
| Cost & Expenses | 10.99B | 9.84B | 4.44B | 1.04B | 593.76M | 535.78M | 446.33M | 325.31M |
| Interest Income | 421.00M | 200.00M | 18.00M | 24.72M | 38.53M | 27.02M | 15.24M | 11.31M |
| Interest Expense | 38.00M | 29.00M | 18.00M | 9.89M | 6.61M | 3.10M | 132.00K | 0.00 |
| Depreciation & Amortization | 621.00M | 348.00M | 232.00M | 31.00M | 31.00M | 24.86M | 20.54M | 15.11M |
| EBITDA | -3.28B | 9.77B | 13.53B | -732.00M | -515.00M | -356.45M | -248.82M | -208.66M |
| EBITDA Ratio | -48.61% | 50.71% | 74.97% | -278.02% | -1,136.06% | -337.33% | -140.60% | -205.50% |
| Operating Income | -4.24B | 9.42B | 13.30B | -763.14M | -545.72M | -413.27M | -269.36M | -223.77M |
| Operating Income Ratio | -62.76% | 48.90% | 74.97% | -278.02% | -1,136.06% | -337.33% | -152.20% | -220.39% |
| Total Other Income/Expenses | 297.00M | 155.00M | -11.00M | 19.00M | 31.28M | 28.86M | 13.36M | 8.60M |
| Income Before Tax | -3.94B | 9.58B | 13.29B | -744.51M | -514.72M | -384.41M | -256.00M | -215.17M |
| Income Before Tax Ratio | -58.37% | 49.71% | 74.90% | -271.24% | -1,071.52% | -313.77% | -144.65% | -211.91% |
| Income Tax Expense | 772.00M | 1.21B | 1.08B | 2.55M | -695.00K | 326.00K | -80.00K | 1.04M |
| Net Income | -4.71B | 8.36B | 12.20B | -747.06M | -514.02M | -384.73M | -255.92M | -216.21M |
| Net Income Ratio | -69.80% | 43.41% | 68.80% | -272.16% | -1,070.07% | -314.04% | -144.61% | -212.94% |
| EPS | -12.34 | 21.26 | 30.31 | -1.96 | -1.55 | -1.17 | -0.68 | -0.58 |
| EPS Diluted | -12.34 | 20.12 | 28.29 | -1.96 | -1.55 | -1.17 | -0.68 | -0.58 |
| Weighted Avg Shares Out | 382.00M | 416.00M | 431.00M | 381.33M | 330.80M | 328.80M | 376.00M | 376.00M |
| Weighted Avg Shares Out (Dil) | 382.00M | 416.00M | 431.00M | 381.33M | 330.80M | 328.80M | 376.00M | 376.00M |
Source: https://incomestatements.info
Category: Stock Reports